Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: Facing the challenge of a proper study design

Critical Reviews in Oncology/Hematology

Volumn 34, Issue 2, 2000, Pages 83-88

  Eskens, Ferry A L M ^a,b   Verweij, Jaap ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical studies; Cytostatic anticancer agents; Design; Phase I; Phase II; Phase III

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; CYTOTOXIC AGENT; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER INHIBITION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TARGETING; HUMAN; METHODOLOGY; MODEL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; CLINICAL TRIALS; DRUG DESIGN; HUMANS; RESEARCH DESIGN;

EID: 0034058605     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00055-X     Document Type: Article

References (13)

1. Kohl N.E., Omer C.A., Conner M.W. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1:1995;792-797.
2. Nørgaard P., Law B., Joseph H. et al. Treatment with farnesyl protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGFα/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 5:1999;35-42.
3. Liu M., Bryant M.S., Chen J. et al. Tumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase in human tumor xenograft models in wap-ras transgenic mice. Cancer Res. 58:1998;4947-4956.
4. Adjei A.A., Erlichman C., Davis J.N. et al. A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;156a.
5. Denis L.J., Verweij J. Matrixmetalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs. 15:1997;175-185.
6. Schellens J., De Klerk G., Swart M. et al. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777. Proc. Am. Ass. Cancer Res. 40:1999;724. (abstract 4780).
7. Liu G., Franssen E., Fitch M.I. et al. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15:1997;110-115.
8. Siu L.L., Rowinsky E.K., Clark G.M. et al. Dose escalation using the modified continual reassessment method (MCRM) in phase I clinical trials: a review of the San Antonio experience. Ann. Oncol. 2(Suppl. (2)):1998;127.
9. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland, WHO offset publication No 40, 1979.
10. Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors, J. Natl. Cancer Inst 2000 (in press).
11. Anderson I.C., Shipp M.A., Docherty A.J.P. et al. Combination therapy including a gelatinase inhibitor and cytotoxic agents reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 53:1993;2087-2091.
12. Moasser M.M., Sepp-Lorenzino L., Kohl N.E. et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA. 95:1998;1369-1374.
13. Sun J., Marfurt J., Blaskovich M.A. et al. Effective combination therapy with the non-thiol farnesyl transferase inhibitor FTI-2148 and taxol, gemcitabine or cisplatinum for human tumor xenografts in nude mice. Proc. Am. Ass. Cancer Res. 40:1999;522. (abstract 3443).